AVEO Pharmaceuticals (AVEO) Getting Somewhat Positive Media Coverage, Study Finds

News coverage about AVEO Pharmaceuticals (NASDAQ:AVEO) has trended somewhat positive recently, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. AVEO Pharmaceuticals earned a coverage optimism score of 0.08 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 45.6999222527481 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

These are some of the media headlines that may have effected Accern Sentiment’s analysis:

How to Become a New Pot Stock Millionaire

AVEO Pharmaceuticals stock opened at $2.64 on Monday. AVEO Pharmaceuticals has a 1-year low of $0.57 and a 1-year high of $4.24. The company has a market capitalization of $307.87, a P/E ratio of -16.50 and a beta of 1.32. The company has a quick ratio of 1.56, a current ratio of 1.56 and a debt-to-equity ratio of -0.45.

AVEO has been the subject of a number of recent research reports. BidaskClub upgraded shares of AVEO Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, March 24th. Zacks Investment Research upgraded shares of AVEO Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, January 9th. Finally, B. Riley reiterated a “buy” rating and issued a $5.00 price objective on shares of AVEO Pharmaceuticals in a research note on Tuesday, January 16th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $4.05.

In other news, major shareholder Ravi Viswanathan purchased 685,676 shares of AVEO Pharmaceuticals stock in a transaction dated Friday, April 6th. The stock was purchased at an average cost of $2.24 per share, for a total transaction of $1,535,914.24. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Peter J. Barris purchased 920,976 shares of AVEO Pharmaceuticals stock in a transaction dated Tuesday, April 10th. The shares were purchased at an average price of $2.30 per share, with a total value of $2,118,244.80. The disclosure for this purchase can be found here. 4.70% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by Week Herald and is the property of of Week Herald. If you are viewing this piece on another domain, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://weekherald.com/2018/04/23/aveo-pharmaceuticals-aveo-getting-somewhat-positive-media-coverage-study-finds.html.

About AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).

Insider Buying and Selling by Quarter for AVEO Pharmaceuticals (NASDAQ:AVEO)

Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply